Bisaro Paul 4

What Happened

• Paul Bisaro, a director of Keenova Therapeutics plc, had restricted stock units (RSUs) settled on June 2, 2026. The filing shows 2,685 RSUs converted into ordinary shares.
• Of the shares related to the vesting, 619 shares were withheld to satisfy tax withholding obligations, and 2,197 RSUs were forfeited back to the issuer under an agreement in exchange for a payment from the issuer to help cover tax obligations. One reporting line lists an exercise/conversion with a $0.00 price for the disposition entry.

Key Details

• Transaction date: June 2, 2026; Form 4 filed June 4, 2026 (within the typical 2-business-day reporting window).
• Reported entries: 2,685 RSUs converted to shares (M); 619 shares withheld for taxes (F); 2,197 RSUs forfeited/disposed to issuer (D). One conversion/disposition line shows $0.00 price.
• Shares owned after the transaction: not specified in the filing.
• Notable footnotes: RSUs settled 1-for-1 into ordinary shares (F1); withholding based on a percentage because Keenova’s shares are not listed/quoted on a recognized market (F2); forfeiture of 2,197 RSUs in exchange for issuer payment to facilitate tax obligations (F3); RSUs granted Aug 14, 2025 and vesting schedule noted (F4, F5).
• Filing also serves as notice to the issuer under Part V of the Companies Act 2014 (remark in filing).

Context

• This is an equity-compensation event (RSU vesting and related tax/forfeiture actions), not an open-market buy or sale. Such transactions are typically routine and relate to compensation and tax settlement rather than a direct signal of insider sentiment.
• For retail investors: purchases are often more informative than routine vesting; here the key items are the withholding and the unusual forfeiture+payment arrangement (issuer assisted with tax obligations), which are administrative/tax-related rather than market-directional.